SCHEMBL392264

SCHEMBL392264

[CH](C=Cc1ccccc1)c1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.72
MAPK1 P28482 2/20 0.59
ALDH1A1 P00352 2/20 0.59
LMNA P02545 2/20 0.59
TRPA1 O75762 2/20 0.59
ALOX5 P09917 1/20 0.59
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
MAPT P10636 2/20 0.48
RECQL P46063 2/20 0.48
POLB P06746 1/20 0.48
CMA1 P23946 1/20 0.46
NFE2L2 Q16236 2/20 0.46
CYP19A1 P11511 1/20 0.46
MAOA P21397 1/20 0.46
HDAC3 O15379 2/20 0.45
HDAC4 P56524 2/20 0.45
HDAC1 Q13547 2/20 0.45
HDAC7 Q8WUI4 2/20 0.45
HDAC2 Q92769 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL392263 1.00 MAOB (0.72) MAOBMAPK1ALDH1A1LMNATRPA1
SCHEMBL5974265 1.00 MAOB (0.72) MAOBMAPK1ALDH1A1LMNATRPA1
SCHEMBL3844783 0.86 MAOB (0.54) MAOBMAPK1ALDH1A1LMNATRPA1
SCHEMBL3847986 0.86 MAOB (0.54) MAOBMAPK1ALDH1A1LMNATRPA1
SCHEMBL3847989 0.86 MAOB (0.54) MAOBMAPK1ALDH1A1LMNATRPA1
SCHEMBL3847304 0.86 MAOB (0.54) MAOBMAPK1ALDH1A1LMNATRPA1
SCHEMBL11091721 0.86 MAOB (0.54) MAOBMAPK1ALDH1A1LMNATRPA1
SCHEMBL3844785 0.86 MAOB (0.54) MAOBMAPK1ALDH1A1LMNATRPA1
SCHEMBL3847301 0.86 MAOB (0.54) MAOBMAPK1ALDH1A1LMNATRPA1
SCHEMBL11498215 0.86 APP (0.60) MAOBMAPK1ALDH1A1LMNATRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110862516-A Cardo structure-containing isatin aromatic hydrocarbon copolymer, and preparation method and application thereof 大连理工大学 2020-03-06 CN claimed
EP-0889913-B1 ALLYL CONTAINING METAL COMPLEXES AND OLEFIN POLYMERIZATION PROCESS DOW GLOBAL TECHNOLOGIES INC (US) 2003-07-02 EP claimed
CN-1214700-A Allyl-containing metal complexes and olefin polymerization process DOW CHEMICAL CO (US) 1999-04-21 CN claimed
US-4672068-A Antihypertensive 1,4-dihydropyridines having a conjugated ester FUJIREBIO KABUSHIKI KAISHA (JP) 1987-06-09 US claimed
CN-113387055-B Film, method for producing film, and bag 住友化学株式会社 2024-06-07 CN disclosed
WO-2024107661-A2 METHODS AND COMPOSITIONS FOR TREATING CANCER ONCONOVA THERAPEUTICS, INC. (US) 2024-05-23 WO disclosed
CN-112724302-B Ethylene-alpha-olefin copolymer, process for producing the same, ethylene resin composition, and film 住友化学株式会社 2023-10-31 CN disclosed
US-11643533-B2 Film, method of producing film, and bag SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2023-05-09 US disclosed
CN-112638997-B Film and packaging container 住友化学株式会社 2023-04-28 CN disclosed
CN-110862516-B Cardo structure-containing isatin aromatic hydrocarbon copolymer, and preparation method and application thereof 大连理工大学 2022-11-18 CN disclosed
CN-115215840-A Compound, organic electroluminescent device and display device 爱思开新材料捷恩智株式会社 2022-10-21 CN disclosed
CN-110352213-B Film 住友化学株式会社 2022-09-09 CN disclosed
US-20030069127-A1 Modified particle,support, catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMTED (JP) 2003-04-10 US disclosed
EP-1275662-A1 MODIFIED PARTICLE, SUPPORT, CATALYST COMPONENT FOR ADDITION POLYMERIZATION, CATALYST FOR ADDITION POLYMERIZATION, AND PROCESS FOR PRODUCING ADDITION POLYMER SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-01-15 EP disclosed
US-20020082280-A1 Method of inhibiting neoplastic cells with benzimidazole derivatives OSI PHARMACEUTICALS, INC. 2002-06-27 US disclosed
EP-1180024-A4 Z-STYRYL SULFONE ANTICANCER AGENTS UNIV TEMPLE (US) 2002-06-19 EP disclosed
EP-1180024-A1 Z-STYRYL SULFONE ANTICANCER AGENTS Temple University of the Commonwealth System of Higher Education (US) 2002-02-20 EP disclosed
US-6348032-B1 POTENT COMPOUNDS THAT INDUCE APOPTOSIS IN NEOPLASTIC CELLS (BUT NOT SUBSTANTIALLY IN NORMAL CELLS), WITHOUT SUBSTANTIALLY INHIBITING PGE-2. CELL PATHWAYS, INC. 2002-02-19 US disclosed
WO-2000057872-A1 Z-STYRYL SULFONE ANTICANCER AGENTS TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2000-10-05 WO disclosed
US-4271186-A Stilbene compounds and insecticidal/acaricidal compositions BAYER AKTIENGESELLSCHAFT (DE) 1981-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020082280-A1 Method of inhibiting neoplastic cells with benzimidazole derivatives MKI67, CCNI, TMBIM6 MAOB 1658/4885MAPK1 3029/4885ALDH1A1 487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.